{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:15:40Z","timestamp":1789604140155,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.bcp.2016.07.012","type":"journal-article","created":{"date-parts":[[2016,7,17]],"date-time":"2016-07-17T19:46:43Z","timestamp":1468784803000},"page":"8-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["New therapeutic strategies for malignant pleural mesothelioma"],"prefix":"10.1016","volume":"123","author":[{"given":"Mara A.","family":"Bonelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fumarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"La Monica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2016.07.012_b0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-642-10862-4_2","article-title":"Epidemiology of mesothelioma and historical background","volume":"189","author":"Craighead","year":"2011","journal-title":"Recent Results Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2016.07.012_b0010","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull. World Health Organ."},{"issue":"2","key":"10.1016\/j.bcp.2016.07.012_b0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jtcvs.2015.09.086","article-title":"What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice","volume":"151","author":"Treasure","year":"2016","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"14","key":"10.1016\/j.bcp.2016.07.012_b0020","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2016.07.012_b0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2016.07.012_b0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","article-title":"Molecular changes in mesothelioma with an impact on prognosis and treatment","volume":"136","author":"Jean","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"28","key":"10.1016\/j.bcp.2016.07.012_b0035","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1556-0864(15)31509-4","article-title":"Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma","volume":"1","author":"van den Bogaert","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2016.07.012_b0055","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s12885-015-1519-z","article-title":"The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma","volume":"15","author":"Ak","year":"2015","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.bcp.2016.07.012_b0060","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2004.10.071","article-title":"Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"22","author":"Weder","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2016.07.012_b0065","first-page":"428","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"issue":"7","key":"10.1016\/j.bcp.2016.07.012_b0070","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.bcp.2016.07.012_b0075","doi-asserted-by":"crossref","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","article-title":"Losses of both products of the Cdkn2a\/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis","volume":"6","author":"Altomare","year":"2011","journal-title":"PLoS ONE"},{"issue":"24","key":"10.1016\/j.bcp.2016.07.012_b0080","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.bcp.2016.07.012_b0085","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.bjc.6604002","article-title":"Nf2\/Merlin: a coordinator of receptor signalling and intercellular contact","volume":"98","author":"Curto","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2016.07.012_b0090","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","article-title":"LATS2 is a tumor suppressor gene of malignant mesothelioma","volume":"71","author":"Murakami","year":"2011","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2016.07.012_b0095","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.bcp.2016.07.012_b0100","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.bcp.2016.07.012_b0105","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2016.07.012_b0110","first-page":"333","article-title":"Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers","volume":"152","author":"Pache","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"23","key":"10.1016\/j.bcp.2016.07.012_b0115","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella","year":"1996","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.bcp.2016.07.012_b0120","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2016.07.012_b0125","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2016.07.012_b0130","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy","volume":"6","author":"Brevet","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2016.07.012_b0135","first-page":"2401","article-title":"Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma","volume":"33","author":"Xin","year":"2013","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2016.07.012_b0140","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bcp.2011.07.073","article-title":"Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1\/2 as antitumor targets","volume":"82","author":"Barbieri","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2016.07.012_b0145","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.3892\/or.2015.4314","article-title":"Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells","volume":"34","author":"Okita","year":"2015","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2016.07.012_b0150","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3892\/ijo.2012.1607","article-title":"Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma","volume":"41","author":"Kurai","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"20","key":"10.1016\/j.bcp.2016.07.012_b0155","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/0008-5472.CAN-04-1898","article-title":"Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes","volume":"64","author":"Hoang","year":"2004","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2016.07.012_b0160","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/ijc.27471","article-title":"Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites\/cell","volume":"131","author":"Kalra","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2016.07.012_b0165","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1042\/BST20150252","article-title":"The role of the HGF\/Met axis in mesothelioma","volume":"44","author":"Thayaparan","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"9","key":"10.1016\/j.bcp.2016.07.012_b0170","doi-asserted-by":"crossref","first-page":"e105919","DOI":"10.1371\/journal.pone.0105919","article-title":"MET and PI3K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma","volume":"9","author":"Kanteti","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2016.07.012_b0175","doi-asserted-by":"crossref","unstructured":"R.P. Kanteti, J.J. Riehm, I. Dhanasingh, F.E. Lennon, H. Kindler, R. Salgia, PI3-Kinase pathway and MET inhibition is efficacious in malignant pleural mesothelioma, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract PP01.04] #.","DOI":"10.1038\/srep32992"},{"issue":"Suppl.","key":"10.1016\/j.bcp.2016.07.012_b0180","article-title":"Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma","volume":"33","author":"Zucali","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"10.1016\/j.bcp.2016.07.012_b0185","article-title":"ARQ 197 in patients with previously-treated malignant mesothelioma (MM): a phase II trial from the University of Chicago Phase II Consortium","volume":"33","author":"Maron","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0190","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","article-title":"Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)","volume":"77","author":"Cedres","year":"2012","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2016.07.012_b0195","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.25555","article-title":"Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma","volume":"117","author":"Varghese","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2016.07.012_b0200","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2016.07.012_b0205","doi-asserted-by":"crossref","first-page":"e36856","DOI":"10.1371\/journal.pone.0036856","article-title":"Perifosine as a potential novel anti-cancer agent inhibits EGFR\/MET-AKT axis in malignant pleural mesothelioma","volume":"7","author":"Pinton","year":"2012","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.bcp.2016.07.012_b0210","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3892\/or.2013.2948","article-title":"Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma","volume":"31","author":"Moriya","year":"2014","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2012.07.005","article-title":"Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy","volume":"78","author":"Fischer","year":"2012","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2016.07.012_b0220","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2016.07.012_b0225","unstructured":"I.R. Powley, X.-M. Sun, T. Chernova, S. Galavotti, S. Grosso, J.Z. Cabeza, J. Le Quesne, J. Bennett, A. Nakas, J.H. Pringle, A.E. Willis, D. Fennell, M. Macfarlane, Evaluation of sensitivity to PI3K\/MTOR and FAK inhibition in pre-clinical models of malignant mesothelioma, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract MS11.03] #."},{"issue":"44","key":"10.1016\/j.bcp.2016.07.012_b0230","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"issue":"19 Suppl.","key":"10.1016\/j.bcp.2016.07.012_b0235","article-title":"VS-6063 (defactinib) targets cancer stem cells directly and through inhibition of tumor-associated macrophages and cytokine production","volume":"74","author":"Pachter","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.07.012_b0240","unstructured":"L. Lievense, F. Dammeijer, M. Van Nimwegen, K. Bezemer, Y. Wang, J. Pachter, J. Hegmans, J. Aerts, Focal Adhesion Kinase inhibition targets macrophages in vitro and in vivo in a mesothelioma mouse model, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract PP02.21] #."},{"key":"10.1016\/j.bcp.2016.07.012_b0245","unstructured":"R. Bueno, W. Richards, R. Gill, J. Barlow, P. Lizotte, K. Wong, M. Bittinger, Y. Wang, L. Vaickus, D.T. Weaver, Phase 2 neoadjuvant study of VS-6063, a FAK inhibitor, in subjects with surgically resectable malignant pleural mesothelioma, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract MS10.04] #."},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1593\/neo.101156","article-title":"Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma","volume":"13","author":"Ou","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2016.07.012_b0255","unstructured":"M. Tagawa, S. Okamoto, T. Morinaga, M. Shingyoji, I. Sekine, T. Suzuki, Y. Tada, K. Tatsumi, H. Shimada, K. Hiroshima, Combination of nutlin-3A and HSP90 inhibitors produces synergistic cytotoxicity on mesothelioma with the wild-type p53, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract PP02.66] #."},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0260","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2016.07.012_b0265","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-07-1388","article-title":"Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts","volume":"14","author":"Bertino","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2016.07.012_b0270","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2016.07.012_b0275","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-07-0501","article-title":"The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice","volume":"13","author":"Li","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"10026","key":"10.1016\/j.bcp.2016.07.012_b0280","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.bcp.2016.07.012_b0285","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2016.07.012_b0290","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2016.07.012_b0295","unstructured":"V. Laszlo, J. Ozsvar, T. Klikovits, D. Lakatos, M.A. Hoda, T. Garay, W. Berger, M. Grusch, W. Klepetko, F. Hilberg, B. Dome, B. Hegedus, Preclinical investigation of the therapeutic potential of nintedanib in malignant pleural mesothelioma, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract PP02.61] #."},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0300","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2016.07.012_b0305","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2016.07.012_b0310","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2016.07.012_b0315","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12885-015-1363-1","article-title":"The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma","volume":"15","author":"Pignochino","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0320","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-006-0243-4","article-title":"Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma","volume":"59","author":"Porta","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2016.07.012_b0325","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cllc.2013.12.008","article-title":"Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma","volume":"15","author":"Tsao","year":"2014","journal-title":"Clin. Lung Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2016.07.012_b0330","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1073\/pnas.0611653104","article-title":"Impaired angiogenesis in aminopeptidase N-null mice","volume":"104","author":"Rangel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.bcp.2016.07.012_b0335","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/81183","article-title":"Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)","volume":"18","author":"Curnis","year":"2000","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0340","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-05-1147","article-title":"Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha","volume":"12","author":"Sacchi","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.bcp.2016.07.012_b0345","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma","volume":"28","author":"Gregorc","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"10.1016\/j.bcp.2016.07.012_b0350","article-title":"Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)","volume":"33","author":"Gaafar","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"12 Pt 1","key":"10.1016\/j.bcp.2016.07.012_b0355","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2016.07.012_b0360","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.bcp.2016.07.012_b0365","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2016.07.012_b0370","unstructured":"B.A. Wallin, K. Hoffman, M. Mclaughlin, R. Hassan, A randomized study of Amatuximab with pemetrexed and cisplatin as frontline therapy for subjects with pleural mesothelioma, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract PP02.35] #."},{"issue":"6","key":"10.1016\/j.bcp.2016.07.012_b0375","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2016.07.012_b0380","unstructured":"R. Hassan, J.C. Bendell, G.R. Blumenschein, H. Kindler, K.N. Moore, A.D. Santin, S.M. Seward, J. Nemunaitis, P. Rajagopalan, A. Walter, N. Sarapa, Phase I study of anti-mesothelin antibody drug conjugate Anetumab Ravtansive in patients with metastatic mesothelioma, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract MS10.01] #."},{"issue":"21","key":"10.1016\/j.bcp.2016.07.012_b0385","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2016.07.012_b0390","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ctrv.2015.09.006","article-title":"Targeting immune checkpoints: new opportunity for mesothelioma treatment?","volume":"41","author":"Marcq","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2016.07.012_b0395","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2016.07.012_b0400","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2016.07.012_b0405","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2016.07.012_b0410","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2016.07.012_b0415","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.bcp.2016.07.012_b0420","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"5899","key":"10.1016\/j.bcp.2016.07.012_b0425","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bcp.2016.07.012_b0430","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2016.07.012_b0435","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tox.2015.10.005","article-title":"Enhancement of regulatory T cell-like suppressive function in MT-2 by long-term and low-dose exposure to asbestos","volume":"338","author":"Ying","year":"2015","journal-title":"Toxicology"},{"issue":"8","key":"10.1016\/j.bcp.2016.07.012_b0440","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-11-1014","article-title":"CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma","volume":"11","author":"Wu","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bcp.2016.07.012_b0445","doi-asserted-by":"crossref","first-page":"e61895","DOI":"10.1371\/journal.pone.0061895","article-title":"Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity","volume":"8","author":"Lesterhuis","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2016.07.012_b0450","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2012.00153","article-title":"Radiation as an immunological adjuvant: current evidence on dose and fractionation","volume":"2","author":"Demaria","year":"2012","journal-title":"Front. Oncol."},{"issue":"14","key":"10.1016\/j.bcp.2016.07.012_b0455","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.18632\/oncotarget.3487","article-title":"Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bcp.2016.07.012_b0460","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2016.07.012_b0465","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","article-title":"Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy","volume":"37","author":"Hoos","year":"2010","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2016.07.012_b0470","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.bcp.2016.07.012_b0475","doi-asserted-by":"crossref","unstructured":"L. Calabro\u2019, A. Morra, D. Giannarelli, D. Annesi, E. Bertocci, R. Danielli, M. Altomonte, A.M. Di Giacomo, M. Maio, Tremelimumab and Durvalumab combination for first and second-line treatment of mesothelioma patients: the NIBIT-MESO-1 study, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract MS10.03] #.","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8575"},{"key":"10.1016\/j.bcp.2016.07.012_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","author":"Combaz-Lair","year":"2016","journal-title":"Hum. Pathol."},{"issue":"4","key":"10.1016\/j.bcp.2016.07.012_b0485","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bcp.2016.07.012_b0490","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 expression in small cell neuroendocrine carcinomas","volume":"51","author":"Schultheis","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"7528","key":"10.1016\/j.bcp.2016.07.012_b0495","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2016.07.012_b0500","doi-asserted-by":"crossref","unstructured":"E.W. Alley, L.R. Molife, A. Santoro, K. Beckey, S. Yuan, J.D. Cheng, B. Piperdi, J.H.M. Shellens, Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028, in: AACR Annual Meeting, 2015, [abstract CT103].","DOI":"10.1158\/1538-7445.AM2015-CT103"},{"key":"10.1016\/j.bcp.2016.07.012_b0505","unstructured":"J. Quispel-Janssen, M. Zimmerman, W. Buikhuisen, S. Burgers, G. Zago, P. Baas, Nivolumab in malignant pleural mesothelioma (NIVOMES): an interim analysis, in: 13th International Conference of the iMig Abstract Book, 2016, [abstract MS04.07] #."},{"key":"10.1016\/j.bcp.2016.07.012_b9000","unstructured":"http:\/\/imig2016.org\/wp-content\/uploads\/2016\/04\/iMig-2016-Abstract-Book.pdf"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216301770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216301770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T08:08:42Z","timestamp":1568189322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295216301770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":102,"alternative-id":["S0006295216301770"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2016.07.012","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New therapeutic strategies for malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}